Janux Therapeutics Inc (JANX) financials
Janux Therapeutics revenue and earnings by year
Janux Therapeutics's revenue was $10.0 million in the fiscal year to December 31, 2025, down 5.6% from the year before. Net income was -$114 million, -1136.3% of revenue. Since the fiscal year to December 31, 2021, revenue has grown 28.8% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 5 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 10 | 11 | 8 | 9 | 4 |
| Revenue growth | -5.6% | 31.0% | -6.1% | 136.8% | — |
| Operating income | -158 | -99 | -73 | -67 | -33 |
| Operating margin | -1576.7% | -933.6% | -902.9% | -779.0% | -905.4% |
| Net income | -114 | -69 | -58 | -63 | -33 |
| Net margin | -1136.3% | -651.6% | -721.2% | -732.2% | -898.3% |
| Diluted EPS | -$1.83 | -$1.28 | -$1.32 | -$1.52 | — |
| Free cash flow | -83 | -44 | -52 | -49 | -18 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open JANX in Markets.
See also: JANX returns
No forecast, no recommendation. This page describes Janux Therapeutics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.